Trial Search Results

GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)

An observational study to evaluate the natural progression of dry AMD in genetically defined subjects

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Gyroscope Therapeutics Limited

Collaborator: Novartis Pharmaceuticals

Stanford Investigator(s):

Eligibility


Inclusion Criteria:

   1. Adults with unilateral or bilateral Geographic Atrophy (GA) due to Age-related Macular
   Degeneration (AMD)

   2. BCVA of 40 letters or better using ETDRS charts

Exclusion Criteria:

   1. Evidence or history of neovascular Age-related Macular Degeneration (AMD) or diabetic
   retinopathy

   2. Significant ocular or non-ocular disease that would impact the subject's ability to
   participate in the study

   3. Participation in another research study involving an investigational product within
   the previous 4 weeks or 5 half-lives whichever is longer from the screening/baseline
   OR received a gene/cell therapy at any time previously

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Recruiting